Alvotech and Teva Pharmaceuticals Collaborate to Expand Access for Adalimumab-ryvk (Interchangeable Biosimilar, Humaira) in US
Shots:
- Alvotech entered into a long-term agreement with Teva Pharmaceuticals to expand access to newly US FDA-approved higher concentration Adalimumab-ryvk, an interchangeable biosimilar to Humaira in US market
- The partnership agreement aims to broaden access and further availability assurance of biologics for patients at affordable prices in the US and globally
- Following commercialization collaboration between companies, SIMLANDI (Adalimumab-ryvk) will be commercialized by Teva in the US
Ref: Alvotech | Image: Alvotech
Related News:- Teva and Alvotech’s Selarsdi (Biosimilar, Stelara) Receives the US FDA’s Approval
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
